News Releases - Rapid Micro Biosystems, Inc.

Year

12 03 / 2026

Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Reports record fourth quarter 2025 total revenue of $11.3 million, representing 37% growth compared to fourth quarter 2024 Reports full year 2025 total revenue of $33.6 million, representing 20% growth compared to 2024 Amgen expands global Growth Direct system rollout with significant multi-system

12 03 / 2026

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform

Companies deepen partnership to advance automated, integrated microbiology quality control LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions

10 03 / 2026

Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum

LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,

26 02 / 2026

Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference

LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,

24 02 / 2026

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,

12 02 / 2026

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,

13 01 / 2026

Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period. Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing

07 01 / 2026

Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,